Podcasts about Myasthenia gravis

In this episode, Sam Ashoo, MD and T.R. Eckler, MD discuss the May 2025 Emergency Medicine Practice article, Emergency Department Management of Patients With Complications of Chronic Neurologic Disease: Parkinson Disease, Myasthenia Gravis, and Multiple Sclerosis Parkinson's DiseaseImportance of maintaining medication schedule for Parkinson's patients Strategies for ensuring patients receive their medications promptly Overview of Carbidopa Levodopa's mechanism of actionMyasthenia GravisDescription of the disease mechanism Importance of assessing respiratory function Diagnostic alternatives like the negative inspiratory force test and counting test Discussion on appropriate emergency department actions and treatments including steroids, plasmapheresis, and IVIGMultiple SclerosisDescription of the disease mechanism Description of the typical patient demographic Discussion on the varied presentation of MS Treatment strategies including high-dose steroids and BaclofenEmergency Medicine Residents, get your free subscription by writing resident@ebmedicine.net 

In today's VETgirl online veterinary continuing education podcast, we interview Dr. Missy Carpentier, DACVIM (Neurology) of Minnesota Veterinary Neurology on myasthenia gravis in dogs and cats. What exactly is myasthenia gravis, and what's the classic presentation in dogs and cats? Tune in to learn how we diagnose it, what the typical signalment is, and most importantly, how to treat myasthenia gravis!

The May 2025 recall features four previously posted episodes on myasthenia gravis. The first episode has Dr. Fredrik Piehl discussing rituximab for new-onset generalized MG. In the second episode, Dr. Vera Bril explores the potential use of immunoglobulin as a corticosteroid-sparing agent in MG patients. The third episode features Dr. Ali A. Habib discussing trends in hospital admissions and in-hospital mortality for adult MG patients. The series concludes with Dr. Jennifer Morganroth addressing the increase in thymectomy procedures post-MGTX trial, disparities in access to these surgeries among different demographic groups, and the rise of minimally invasive surgical techniques. Podcast links: Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis  Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis Hospitalizations and Mortality from MG Hospitalizations and Mortality From Myasthenia Gravis Trends and Disparities in the Utilization of Thymectomy for MG in the US Article links: Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis Hospitalizations and Mortality From Myasthenia Gravis Trends and Disparities in the Utilization of Thymectomy for Myasthenia Gravis in the United States Disclosures can be found at Neurology.org.

Biopharma companies are vying to dethrone Vyvgart as a leading therapy for myasthenia gravis, with the latest data for therapies treating the rare autoimmune neuromuscular disease coming at this month's American Academy of Neurology. On a special episode of the BioCentury This Week podcast, BioCentury's editors discuss the landscape for MG therapies, including anti-BLyS and APRIL therapy telitacicept from Remegen. Joining BioCentury's editors are Qing Zuraw, chief development officer of podcast sponsor RemeGen, and Amit Sachdev, PI on global trials of the biotech's therapy. BioCentury's editors also preview the American Association for Cancer Research annual meeting, where degraders and bispecifics are defining translational trends at this year's event. This episode of BioCentury This Week podcast was sponsored by RemeGen.View full story: https://www.biocentury.com/article/655751#biotech #biopharma #pharma #lifescience #AAN #AACR00:01 - Sponsor Message: RemeGen Co.01:02 - Myasthenia Gravis at AAN08:31 - RemeGen's Telitacicept18:03 - AACR: Targets and TrendsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

A 70-year-old client fills in an online intake form, saying she has myasthenia gravis, hypertension, and hypothyroidism. She only takes Synthroid, and says her hypothyroidism and hypertension are well controlled. She has low back pain and muscle soreness. At first glance, this seems fairly simple. MG does not appear to be a major factor for her, because she is not controlling it with medication. But a closer look reveals some possible tangles between MG, hypothyroidism, and some cautions about hypertension drugs. Join me as I completely overthink this situation, it will be fun!   Resources:   Barnes, S. (2023) Massage is not just a luxury for those of us with myasthenia gravis | Myasthenia Gravis News. Available at: https://myastheniagravisnews.com/columns/massage-is-not-just-luxury-those-us-with-myasthenia-gravis/ (Accessed: 16 April 2025).   Myasthenia Gravis (no date a) Physiopedia. Available at: https://www.physio-pedia.com/Myasthenia_Gravis (Accessed: 16 April 2025).   Myasthenia Gravis (no date b). National Library of Medicine. Available at: https://medlineplus.gov/myastheniagravis.html (Accessed: 16 April 2025).   Myasthenia Gravis | National Institute of Neurological Disorders and Stroke (no date). Available at: https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravis (Accessed: 16 April 2025).   Myasthenia gravis - causes, symptoms, treatment, pathology (2016). Available at: https://www.youtube.com/watch?v=bYGxGdu9MsQ (Accessed: 16 April 2025).   ‘Myasthenia Gravis: Practice Essentials, Background, Anatomy' (2024). Available at: https://emedicine.medscape.com/article/1171206-overview (Accessed: 16 April 2025).   Myasthenia Gravis: What Is It? (no date) Cleveland Clinic. Available at: https://my.clevelandclinic.org/health/diseases/17252-myasthenia-gravis-mg (Accessed: 16 April 2025).   Sheikh, S. et al. (2021) ‘Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update', Journal of Clinical Medicine, 10(7), p. 1537. Available at: https://doi.org/10.3390/jcm10071537.     Host Bio:                    Ruth Werner is a former massage therapist, a writer, and an NCBTMB-approved continuing education provider. She wrote A Massage Therapist's Guide to Pathology, now in its seventh edition, which is used in massage schools worldwide. Werner is also a long-time Massage & Bodywork columnist, most notably of the Pathology Perspectives column. Werner is also ABMP's partner on Pocket Pathology, a web-based app and quick reference program that puts key information for nearly 200 common pathologies at your fingertips. Werner's books are available at www.booksofdiscovery.com. And more information about her is available at www.ruthwerner.com.      About our Sponsors:   Anatomy Trains: www.anatomytrains.com    American Massage Conference: www.massagetherapymedia/conferences   Earthlite: www.earthlite.com   Anatomy Trains is a global leader in online anatomy education and also provides in-classroom certification programs for structural integration in the US, Canada, Australia, Europe, Japan, and China, as well as fresh-tissue cadaver dissection labs and weekend courses. The work of Anatomy Trains originated with founder Tom Myers, who mapped the human body into 13 myofascial meridians in his original book, currently in its fourth edition and translated into 12 languages. The principles of Anatomy Trains are used by osteopaths, physical therapists, bodyworkers, massage therapists, personal trainers, yoga, Pilates, Gyrotonics, and other body-minded manual therapists and movement professionals. Anatomy Trains inspires these practitioners to work with holistic anatomy in treating system-wide patterns to provide improved client outcomes in terms of structure and function.                      Website: anatomytrains.com                        Email: info@anatomytrains.com             Facebook: facebook.com/AnatomyTrains                       Instagram: www.instagram.com/anatomytrainsofficial   YouTube: https://www.youtube.com/channel/UC2g6TOEFrX4b-CigknssKHA      American Massage Conference Get ready to immerse yourself in the excitement as the American Massage Conference (AMC) arrives to Disney Springs near Orlando, Florida (May 16th-18th, 2025)! With a legacy of 17 successful years in Ontario, Canada, this premier event, proudly hosted by ONE Concept Conferences and expertly produced by Massage Therapy Media (MTM), boasts a lineup of presenters from across the nation and around the globe. The American Massage Conference began in Atlanta in 2011 and has been hosted through the years in San Diego, Chicago, and Virginia Beach. The conference provides educational opportunities with engaging one-, two-, three- and four-hour class formats, networking opportunities, masterminds, MTM Talks, demonstrations, and an extensive exhibitor tradeshow.   Mark your calendars for an unforgettable experience filled with education, networking, and the celebration of massage therapy excellence! ABMP members receive a special discount to attend this in-person conference—log in to your ABMP account to access the discount code and register today. Website: https://www.massagetherapymedia.com/conferences   Earthlite Unlock an exclusive 20 percent discount on all Earthlite products, from portable tables and chairs to professional sheets and oils. Visit earthlite.com, create an account, and enter your ABMP member ID during registration. Plus, enjoy free ground shipping on orders over $75 and a flat rate of $395 for stationary or electric lift tables. (Prices subject to change at any time.) Significant savings on everything you need to enhance your practice. We are proud to assist you as the “World's No. 1 Brand in Massage!”   Sign-up page: https://www.earthlite.com/customer/account/login/referer/aHR0cHM6Ly93d3cuZWFydGhsaXRlLmNvbS8~/  

What's the problem with antibiotics anyway? On this episode of Vitality Radio, Jared passionately answers this question. There is no antibiotic that doesn't cause harm. That's not to say they don't have their place, but as Jared explains, they are almost never necessary and almost always prescribed for common problems like UTI's and sinus infections. You'll learn why many infections don't need, and won't respond to antibiotics, the ramifications of even a single dose of antibiotics, and how antibiotic superbugs are a real problem. Jared delves into why antibiotics are overused, side effects of particularly dangerous forms, and the effects on mental health and the immune system. This show will be followed with one on antibiotic alternatives and ways to rebuild your microbiome after antibiotic exposure.Additional Information:#264: Emotional Vitality: Jen's Story Part 1 - From Addiction and Mental Illness to Vitality#266: Prescribing Poisons Part 2. Ibuprofen, PPI's, and Flouroquinalone AntibioticsVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

Patients with refractory or high-risk myasthenia gravis (MG) respond poorly to conventional immunosuppressive therapy, requiring rescue therapies and often experiencing treatment toxicity. The study discussed in this podcast suggests that lower doses of cyclophosphamide can be effective and safe in people with MG, including older age. JNNP's podcast editor, Saima Chaudhry, is joined by Professor Carolina Barnett-Tapia, University of Toronto, University Health Network, who authors the editorial comment 'Cyclophosphamide for myasthenia gravis: a comeback?'(https://jnnp.bmj.com/content/95/12/1095). The original paper is also free to access: https://jnnp.bmj.com/content/95/12/1096. Please subscribe to the show on Apple Podcasts, Spotify or find it on your platform of choice. Your feedback and reviews are very appreciated. Follow JNNP on twitter: @JNNP_BMJ

On episode #78 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 3/27/25 – 4/9/25. Hosts: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Demise of the Milwaukee protocol for rabies (CID) A natural experiment on the effect of herpes zoster vaccination on dementia (Nature) Taking a shot at dementia(microbeTV: TWiV) Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirusin patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies (LANCET: Infectious Diseases) Epstein-Barr virus exposure precedes Crohn`s disease development (Gastroenterology aga) Bacterial Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older (GSK) GSK wins FDA nod for first oral UTI antibiotic in almost 30 years(BioSpace) Efficacy and safety of individualised versus standard 10-day antibiotic treatment in children with febrile urinary tract infection (INDI-UTI): a pragmatic, open-label, multicentre, randomised, controlled, non-inferiority trial in Denmark (LANCET: Infectious Diseases) Frequency and severity of Myasthenia Gravis exacerbations associated with the use of ciprofloxacin, levofloxacin, and azithromycin (Muscle & Nerve) The cost of blood cultures: a barrier to diagnosis in low-income and middle-income countries (LANCET: Microbe) Rethinking blood culture (LANCET: Microbe) Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data and Outcomes(CID) Fungal The Last of US Season 2 (YouTube) Cracks in the curriculum: the hidden deficiencies in fungal disease coverage in medical books (OFID) Kazachstania slooffiae fungemia: a case report and literature review on an emerging opportunistic pathogen in humans (OFID) Plasma microbial cell-free DNS metagenomic sequencing for diagnosis of invasive fungal diseases among high risk outpatient and inpatient immunocompromised hosts (CID) Parasitic Fatal Case of Splash Pad–Associated Naegleria fowleri Meningoencephalitis — Pulaski County, Arkansas, September 2023 (CDC: MMWR) Notes from the Field: Fatal Acanthamoeba Encephalitis in a patient who regularly used tap water in an electronic nasal irrigation device and a continuous positive airway pressure machine at home — new Mexico, 2023 (CDC: MMWR) Malaria (NEJM) Miscellaneous FDA grants marketing authorization of first home test for chlamydia, gonorrhea and trichomoniasis (FDA) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis

James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis

James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis

James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis

James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis

James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis

Learn from experts in the field on the pharmacist's role in Myasthenia Gravis. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Learn from experts in the field on the pharmacists role in Myasthenia Gravis. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

To mark International Rare Disease Day, we're going to introduce you to a remarkable young woman, Zainab Alani, who is not letting her challenging rare condition stand in the way of her dream of becoming a physician. After noticing Zainab's struggles with muscle weakness and fatigue at age 15, her mother – a physician – took her to doctors advocating for a diagnosis of the rare autoimmune condition generalized myasthenia gravis (MG). Unfortunately, a series of clinicians attributed her symptoms to her menstrual cycle and other errant causes and even accused Zainab of being ‘a lazy teenager.' “Despite having that support and knowledge behind me, these doctors were dismissing my symptoms because of that deceiving label of rare,” Zainab explains to host Lindsey Smith. Wanting to spare others from this frustrating diagnostic odyssey, Zainab turned to advocacy once in medical school and is working with her sister and others through the organization Rare Aware Glasgow to raise awareness among the general public about rare conditions and to spur the medical community to adjust its perspective. “We don't expect medical professionals to know every single rare disease, we just want them to acknowledge their existence and not dismiss them when a family member or a patient brings them up as a differential diagnosis.” In this inspiring episode in our Year of the Zebra podcast series you'll also learn about intersectionality creating burdens in medical diagnosis and a questionable basis for patients being denied access to new treatments.Mentioned in this episode:Rare Aware GlasgowThe Myasthenia Medic If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

In this episode, we review the high-yield topic⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Myasthenia Gravis⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠from the Neurology section at ⁠⁠⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026.Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026.Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026.Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026.Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026.Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026.Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026.Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026.Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

In this episode we will discuss Myasthenia Gravis, an Autoimmune Disease affecting the neuromuscular system of the body with Tasha White, Director of a new Non-profit organization called My Walk with MG located in St. Louis, MO. ​ Myasthenia gravis is a chronic neuromuscular disease that causes weakness in the voluntary muscles. Voluntary muscles include muscles that connect to a person's bones, muscles in the face, throat, and diaphragm. They contract to move the arms and legs and are essential for breathing, swallowing and facial movements. Myasthenia gravis is an autoimmune disease, which means that the body's defense system mistakenly attacks healthy cells or proteins needed for normal functioning. The onset of the disorder may be sudden. Symptoms may not be immediately recognized as myasthenia gravis. The degree of muscle weakness involved varies greatly among individuals.    

Dr Philip Ambrose talks us through recent advancements in MG and managemnt of myasthenic crisis

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-in-myasthenia-gravis-crafting-personalized-treatment-strategies/32244/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/fcrn-antagonists-in-myasthenia-gravis-a-new-era-in-targeted-therapy/32242/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

Dr. Stacey Clardy discusses when to test for myasthenia gravis in this lab minute. 

Understanding Myasthenia Gravis, including pathophysiology and causes. Also features Myasthenia Gravis symptoms (and crisis!), as well as diagnosis and treatment. Consider subscribing on YouTube (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Patreon: https://www.patreon.com/rhesusmedicineBuy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 What is Myasthenia Gravis?0:19 Myasthenia Gravis Pathophysiology1:38 Myasthenia Gravis Symptoms3:44 Myasthenia Gravis Causes4:30 Myasthenia Gravis Diagnosis 6:15 Myasthenia Gravis TreatmentReferencesBMJ Best Practice (2024) - “Myasthenia Gravis”. Available at https://bestpractice.bmj.com/topics/en-gb/238National Institute of Neurological Disorder and Stroke - “Myasthenia Gravis”. Available at https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravisRubin, M - MSD Manual Pro (2024) - “Myasthenia Gravis”. Available at https://www.msdmanuals.com/professional/neurologic-disorders/peripheral-nervous-system-and-motor-unit-disorders/myasthenia-gravisMyasthenia Gravis Foundation Of America - “Cautionary Drugs”. Available at https://myasthenia.org/living-with-mg/mg-emergency-preparedness/cautionary-drugs/Phillips, D. W (2016) - “Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms**”.** Available at https://pmc.ncbi.nlm.nih.gov/articles/PMC4926737/MyastheniaGravis.Com - Available at https://myasthenia-gravis.com/Please remember this podcast and all content from Rhesus Medicine is meant for educational purposes only and should not be used as a guide to diagnose or to treat. Please consult a healthcare professional for medical advice. 

Pushpa Narayanaswami, MD, FAAN - Cutting Through the Congress Cacophony on Generalised Myasthenia Gravis: Expert Honing of the Latest Data

Pushpa Narayanaswami, MD, FAAN - Cutting Through the Congress Cacophony on Generalised Myasthenia Gravis: Expert Honing of the Latest Data

Dr Philip Ambrose, consultant Neurologist in Nottingham University Hospitals NHS Foundation Trust, discussed more about investigations and treatment of Myasthenia Gravis.  

In this episode, I am joined by Nicholas Silvestri, Professor of Neurology at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences, where he is also Associate Dean for Student and Academic Affairs. He is board-certified in neurology, neuromuscular medicine, and electrodiagnostic medicine.Over the past several years, Nicholas Silvestri's research interests have included myasthenia gravis and inflammatory neuropathies, and he has authored over 60 peer-reviewed articles, book chapters, and textbooks.Our conversation covers the full spectrum of myasthenia gravis – from its pathology and pathogenesis to its clinical features, investigations and treatments. He explains such tricky areas of myasthenia gravis, such as why the antibody levels do not correlate with clinical severity of the disease, and why the disease frequently starts in the ocular muscles.We also explored such themes as why anti MUSK myasthenia gravis favours Black people and those living around the equator, and why steroid treatment may worsen myasthenic symptoms.Nicholas Silvestri also discussed the newer and more effective treatments of refractory myasthenia gravis, and how he manages the different facets of the disease.

In this episode I explore the autoimmune neurological disorder, myasthenia gravis. I review its classical manifestations as ocular and generalised myasthenia, and I highlight its complications such as refractory myasthenia and myasthenic crisis.The podcast also discusses the pathogenesis and triggers of the disease, its various mimics, and its indispensable investigations. I also review its treatments which include acetylcholine esterase inhibitors, steroids, immunosuppressants, IVIg and plasma exchange.I complement the podcast with historical anecdotes regarding the discoveries, frequently serendipitous, of the various treatments of myasthenia gravis. This narrative includes such stories as Mary Walker's miracle of Alfege's, the dream insight of Otto Loewi, the mystery of the headless torso in the Thames, and the role played by the Calabar bean in the history of myasthenia gravis. Other relevant historical themes were the role played by Alfred Blalock in introducing thymectomy for myasthenia gravis, and the first serendipitous self-treatment of myasthenia gravis by medical student Harriet Edgeworth.I rely on such illustrative patient memoirs as those of Kemi Olawaiye-Dampson titled Living with Myasthenia Gravis, of Howard Caras titled Permanent Detour, and of Ronald Henderson titled Attacking Myasthenia Gravis.I also cited such enlightening academic sources as Coping with Myasthenia Gravis, by Aziz Shaibani and colleagues, and The Spark of Life by Frances Ashcroft.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JDS865. CME credit will be available until November 16, 2025.Steering Away From Steroids in Myasthenia Gravis Management: The Role of FcRn Inhibitors in the Current Treatment Paradigm In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JDS865. CME credit will be available until November 16, 2025.Steering Away From Steroids in Myasthenia Gravis Management: The Role of FcRn Inhibitors in the Current Treatment Paradigm In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JDS865. CME credit will be available until November 16, 2025.Steering Away From Steroids in Myasthenia Gravis Management: The Role of FcRn Inhibitors in the Current Treatment Paradigm In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JDS865. CME credit will be available until November 16, 2025.Steering Away From Steroids in Myasthenia Gravis Management: The Role of FcRn Inhibitors in the Current Treatment Paradigm In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JDS865. CME credit will be available until November 16, 2025.Steering Away From Steroids in Myasthenia Gravis Management: The Role of FcRn Inhibitors in the Current Treatment Paradigm In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JDS865. CME credit will be available until November 16, 2025.Steering Away From Steroids in Myasthenia Gravis Management: The Role of FcRn Inhibitors in the Current Treatment Paradigm In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure information is available at the beginning of the video presentation.

Jointly Provided by the American Academy of CME and CheckRare CE Inc.Support for this accredited continuing education activity has been made possible through educational grant from argenx US Inc. and UCB.Estimated time to complete: 0.25 hoursStart date: November 7, 2024End date: November 6, 2025This quarter-hour CME-accredited program, hosted by Richard J. Nowak, MD, MS, discusses the safety and efficacy of neonatal fragment crystallizable receptor (FcRn)-directed therapies for patient with myasthenia gravis.To obtain CME credit, visit https://checkrare.com/learning/p-fcrn-and-myasthenia-gravis-treatment-options/ Activity FacultyRichard J. Nowak, MD, MSDirector, Program in Clinical & Translational Neuromuscular Research (CTNR) Director, Yale Myasthenia Gravis Clinic Associate Professor of Neurology Division of Neuromuscular MedicineDepartment of Neurology Yale School of Medicine New Haven, CTTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology and ophthalmology who may be involved in the diagnosis and care of individuals with MG. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe the efficacy of the treatment options for MG that target FcRn.Compare the safety of the treatment options for MG that target FcRn.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Dr. Nowak discloses the following relevant financial relationships with ineligible companies:Advisory Board/Consultant: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBGrant/Research Support: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2024. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s). 

Jointly Provided by American Academy of CME Inc and CheckRare CE Inc.Support for this accredited continuing education activity has been made possible through an educational grant from argenx US Inc.and UCB.Estimated time to complete: 0.25 hoursStart date: November 7, 2024End date: November 6, 2025This quarter-hour CME-accredited program, hosted by Richard J. Nowak, MD, MS, explains the role of  neonatal fragment crystallizable receptor (FcRn) in myasthenia gravis (MG).To obtain CME credit, visit https://checkrare.com/learning/p-fcrn-and-myasthenia-gravis-pathophysiology/ Activity FacultyRichard J. Nowak, MD, MSDirector, Program in Clinical & Translational Neuromuscular Research (CTNR) Director, Yale Myasthenia Gravis Clinic Associate Professor of Neurology Division of Neuromuscular MedicineDepartment of Neurology Yale School of Medicine New Haven, CTTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology and ophthalmology who may be involved in the diagnosis and care of individuals with MG. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe the role of FcRn in MG.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Nowak discloses the following relevant financial relationships with ineligible companies:Advisory Board/Consultant: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBGrant/Research Support: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection.Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2024. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s). 

Jointly Provided by American Academy of CME Inc and CheckRare CE Inc.Support for this accredited continuing education activity has been made possible through an educational grant from argenx US Inc. and UCB.Estimated time to complete: 0.50 hoursStart date: November 7, 2024End date: November 6, 2025This half-hour CME-accredited program, hosted by Richard J. Nowak, MD, MS, explains the role of  neonatal fragment crystallizable receptor (FcRn) in myasthenia gravis (MG) and how treatments that target FcRn are being used to manage patients with MG.To obtain credit, visit https://checkrare.com/learning/p-fcrn-and-myasthenia-gravis/ Activity FacultyRichard J. Nowak, MD, MSDirector, Program in Clinical & Translational Neuromuscular Research (CTNR) Director, Yale Myasthenia Gravis Clinic Associate Professor of Neurology Division of Neuromuscular MedicineDepartment of Neurology Yale School of Medicine New Haven, CTTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology and ophthalmology who may be involved in the diagnosis and care of individuals with MG. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe the role of FcRn in MG.Describe the efficacy of the treatment options for MG that target FcRn.Compare the safety of the treatment options for MG that target FcRn.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Dr. Nowak discloses the following relevant financial relationships with ineligible companies:Advisory Board/Consultant: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBGrant/Research Support: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2024. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s). 

For this special season three finale, Martine is joined by Kathy Perez, Head of Global Patient Advocacy at argenx. They reflect on some of the most impactful and moving moments from guests this season. Kathy asks Martine about her favorite learnings and takeaways as host of the show. While life with autoimmune conditions like MG or CIDP includes a wide range of emotions, Kathy and Martine dig into perhaps the strongest of them all: hope. Whether managing frustrations or juggling the physical changes and pain, hope is what continues to shine through as a beacon for perseverance. Together, Kathy and Martine underscore the transformative power of sharing each untold story, building a strong community, and demonstrating how fostering hope becomes armor for adversity.See omnystudio.com/listener for privacy information.

In 2007, Tony's MG journey began with severe double vision, quickly leading to several episodes of pneumonia. He was in and out of the hospital and rehab facilities for many years, only reaching his MG diagnosis in 2014. Through it all, he was supported by his wife and tireless caregiver, Catherine, documenting every step along the way. From the start, Tony remained determined to regain his strength and to raise awareness for MG. His curiosity and drive led him to become a voice for the MG community across Canada. Though his life changed drastically, Tony embraced the grieving process for the life he once knew and found ways to cherish his new reality.See omnystudio.com/listener for privacy information.

 I've been doing this for about nine months now. And I think it's time that I shared a little bit more about how I got here, and maybe that'll help you on your own health journey. I'd like to think about where you are now, where you've been and where you want to go. So let me tell you where I've been.  I started my OBGYN practice when I was 30 years old. I had a daughter who was just starting kindergarten, and a little boy who was about to turn 2. And my practice ramped up really fast, And back in those days, drug reps often brought lunch to clinic, and they didn't bring healthy stuff. They brought things like pasta with alfredo sauce, and they brought a lot of cheesecake. And I love cheesecake. Especially turtle cheesecake with all that caramel sauce over it. Mmm. It's delicious.  And so every time that they brought dessert, I indulged in dessert. And my life was kind of busy.  I began to gain weight. And I developed migraine headaches. And I wasn't sleeping very well. And of course you can't sleep well when you're an OB doctor anyway, but that's a different story. And so I really felt terrible. On top of that, every single time it was somebody's birthday at the office, we pot lucked and the potlucks weren't much healthier than the drug rep lunches. And they always included birthday cake because after all we were celebrating. But every celebration isn't my own special occasion. But I didn't realize that. So I just plowed on through and next thing you know,  I gained about 15 pounds. Between ages 30 and 35, I felt worse than I had ever felt in my entire life. And I looked it too. I was miserable. My clothes were tight. I didn't have any energy. And I just felt bad. And I discovered a book called, What the Bible Says About Healthy Living, by Dr. Rex Russell, M. D. And so I read this book and it talked about how we should eat things in their natural state. And back then we didn't really use the term whole foods, but eat food in its natural state. And so what Dr. Russell said is that butter is better than margarine, and that vegetables are better than processed foods, and that things that are refined have lost their nutrients, such as white rice, white flour, and sugar. And so I went on a pretty radical diet and I changed my eating habits completely. And the three things I cut out were white rice, white flour, and sugar. And not only did I lose the weight, but my migraine headaches went completely away. Now, I wasn't pure about it. I would obviously indulge every once in a while. And I learned just about how many bites of something I could take before I'd get a headache. So, I would pre decide what I was gonna do if there was a potluck at work. And there was cake, or there was that turtle cheesecake that I could never resist, and I would tell myself, Four bites. That's all you get. Four bites. And most of the time I would stick to that, but every once in a while, I'd just finish the whole piece. And you know what? I'd get a migraine headache. And so, that was a good feedback thing for me to say, You know what? That's a headache on a plate. I don't even want it. Now, I didn't follow what Dr. Russell recommended exactly, He recommended very small intake of meat, but I just kind of ignored that part and the dairy part he recommended butter. So I really lathered the butter on and I did switch to whole wheat. I bought a mill and I started milling my own wheat and making bread.  I discovered a lady named Sue Becker that does bread baking and I had a whisper meal. You just put whole wheat in the top of it and, Grind it up and you get fresh whole wheat flour. And I made bread with olive oil and honey and it was delicious. And so I did that for many, many years and taught my kids to eat healthy. And I'm so thankful for those foundations because My kids have pretty good eating habits, and I think those early years of us eating more whole food was good, even though we ate a lot of vegetables out of the can. We did, because we were on the go, go, go. But we ate vegetables, and we didn't eat a lot of junk food. I followed most of the principles from this book. One of the things he said is that God gave us all of these laws for a clean diet. And then Jesus came and set us free from all those laws, but God knows our body. and he knows how they function best.  And so I followed this diet for many, many years and felt great. I got really fit in my forties and I started exercising after I lost that weight. I felt so good. I wanted to exercise. And so I started cycling and I rode my bike all the time. And then, when I turned 50, my whole world turned upside down. I developed a rare autoimmune disease called Myasthenia Gravis. And it came on pretty suddenly, and I had a severe case of it. I could walk across the room, but I couldn't walk very far. And I couldn't use my arms very much either. And I was very disabled. And to treat me, they put me on a lot of different medications. I had surgery, I had infusions. And, one of the medications made me severely diabetic, so I was on Januvia, Metformin, and insulin for the diabetes. And, to some degree, I think I thought, well, pfft, I ate healthy all those years, what good did that do me? Now, I only paid attention to nutrition, diet. and physical fitness and I treated rest like a four letter word and I did not sleep and I'm not sure if that contributed to my autoimmune disease or not but there is some data that shows that that is a risk factor I kinda threw my hands up in exasperation and said well I've eaten healthy all these years forget it I'm just gonna eat whatever I want but because of the diabetes I couldn't do that. Now it was steroid induced diabetes And I was on prednisone, so my face was as big as a moon. I gained about 8 pounds is all I gained, which is pretty good for that high of a dose of steroids. But it was all from the collarbone up. I mean, it was awful. And to keep my blood sugar from going up too high, I found some things that I could do, like eat nuts, that kept me feeling full, without getting a lot of sugar and unhealthy carbs. And so I was able to avoid an excessive weight gain on the prednisone. And after I got off the prednisone, the weight came off, the diabetes went away, and I went about my merry way eating whatever I wanted to, because the migraines went away with menopause, and like I said, my health was kind of tanked anyway. I thought, what difference does it make?   And then I had some routine blood work done, and it showed an elevated cholesterol, which runs in my family. Everybody in my family has it. I've had it since I was in my 20s. And it also showed an elevated hemoglobin A1c. And so when I went to see my doctor, he looked at me and he said, Are you willing to make some radical changes? And I said, I will do anything to not be diabetic because I knew how terrible I felt when I was diabetic.  And he recommended that I read a book called, How Not to Die, by Dr. Michael Greger. And so I read the book and I started implementing the things that he suggested. And lo and behold, my hemoglobin A1c, normalized and my cholesterol went down as well. And so a little bit after that, I discovered the entire field of lifestyle medicine and the six pillars, which are nutritional eating, and it is plant based, and physical fitness, social connectedness, stress management, restorative sleep, and minimizing exposure to harmful substances. And so I became board certified in lifestyle medicine in December. My lifestyle is pretty good; overall I feel pretty good for 60 and I exercise. I have had a few other health scares recently. And so I decided that I was going to get really strict. And you can probably guess that I read a book. Because I always read a book. And so I read Dr. Neal Barnhart's book, The Power Foods Diet. And I started doing what he recommended in that book, and boom, like that I lost eight pounds. Did I need to lose 8 pounds? Yeah, I did. I mean, I was pretty comfortable in my clothes, and I had been the same weight for, gosh, so many years. But I had developed some belly fat after menopause, and it melted away in a very short period of time following that diet. And he's vegan, and there is a difference between vegetarian and vegan. Vegan is to protect the environment. and to make sure that animals are not mistreated.   And you can eat a vegan diet that's very unhealthy. You can eat a Pop Tart and that is vegan, but it's not healthy. Vegetarian means that you only eat vegetables and you don't eat meat. And I'm not a vegetarian. I eat plant based. And what that means is I get the majority of my calories from whole foods that are nutrient dense. that are plants.  Do I eat meat? Well, sure. I eat meat, just not very often. And originally, when I started doing this, I was cooking for myself and for my husband. And so, for example, I would make stir fry, and then I would do a little chicken for him to add. Or, you know, whatever dish I was making, I might do black bean tacos or mushroom tacos, and I'd do a little ground beef for him. And then he said, you know what, I think I want to try one plant based meal a week. And so we started having one plant based meal a week. And then as my cooking got better, because my cooking has definitely got better, in the plant based department. I learned to make meatballs that don't have any meat in them and they're delicious. And so now he said,  you know, I think I could do two nights a week that are plant based. And I never said anything. I didn't say, Hey, I want you to eat like I'm eating. But I feel really good now. Am I a hundred percent healthy? I'm not, I have issues, but I want to preserve my health as best as I can as I age. And I want to feel good and be able to do all the things that I love to do. And so, I hope that this helps you know that you're not going to do it perfectly. And there's a lot of conflicting information out there. And one of the things I do on this podcast is try to help you sort through the noise. The podcast is really growing and I appreciate everyone who takes time to listen. I'm offering a couple of new things. Number one is the Healthy Looks Great On You Lab. Think of the podcast like the classroom, because we always go to mini medical school and learn something. Think of the Healthy Looks Great On You Lab as the field trip. It's where we go out of the classroom and actually do things that make a difference, because that's my goal. I want to give you information and motivation and inspiration to make changes that make a difference.  So I hope you're on my email list so you get an invitation to the Healthy Looks Great On You Lab. It's going to be so much fun. And if you're like me and you struggle with sleeplessness, I have a webinar coming up that will be free. on sleep. It's called the Sleep Solution. I'll put a link to sign up in the show notes. Registration is open now  and I hope you'll join me for this important information.  And since we didn't go to many medical school today, let me take you behind the scenes and on a day in the life of a doctor. Every morning, I got up, got my kids fed, got them off to school, sometimes took them to school, went to the hospital, made rounds, checked on anybody that was in labor or did surgeries that I had scheduled, then went to the office and saw 40 patients a day, and I never got through before 1 o'clock, so when I did eat, I was rushed, I was just cramming something in my mouth real quick, and go, go, go, go, go, until I got off in the evening, and then home to eat dinner. Then football games to watch my daughter cheer or track meets to watch my son pole vault. Then we'd come home and go to bed and I might get called out two or three times during the night  to deliver a baby.  And we'd get up the next day, whether I'd slept or not, and do it all over again.  I'll be honest with you, it's not an easy life.   But it is so worth it. I always say, nothing compares to the feel of newborn baby feet, except the look in a mother's eyes when she touches them for the first time.  I loved being an OB GYN doctor, And I got some unique insight into a woman's soul.  I consider it an honor and a privilege. And I consider it an honor and a privilege to educate you about lifestyle medicine. I hope you'll stick with me on this journey. We're going to have a great time. Sign up to get my emails. Sign up for the sleep webinar.  There'll be more to come. And I hope to see you in the Healthy Looks Great On You lab.  Because healthy really does look great on you.  Priority access to free sleep webinar Sign up for THE LAB Get podcasts and resources by email

In the final episode of this two-part series, Dr. Joe Conway will discuss four biologic therapies that have been approved in recent years by the FDA for the treatment of adults with generalized myasthenia gravis. In this episode, he will talk about two of the treatment medications: Ravulizumab + zilucoplan. Show references: https://doi.org/10.1016/s1474-4422(21)00159-9 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00077-7/abstract